Key result
Administration of UHRA-9 or UHRA-10 significantly reduced arterial thrombosis in mice with significantly less bleeding compared with therapeutically equivalent doses of heparin.
Why the study?
Do UHRA compounds reduce thrombosis with less bleeding compared to heparin in mouse models?
Population
Mouse models of thrombosis and hemostasis
Comparison
Universal heparin reversal agents vs Therapeutically equivalent doses of heparin
Design
Preclinical
Authors
Loading...
Supports safer antithrombotic development in preclinical models; leaves open human translation of UHRA compounds.
Do UHRA compounds reduce thrombosis with less bleeding compared to heparin in mouse models?
Novel polyphosphate inhibitors (UHRA-9 and UHRA-10) reduce arterial thrombosis in mice with significantly less bleeding than heparin, offering a potential new platform for safer antithrombotic agents.
Travers et al. (2014) studied Thrombosis. Universal heparin reversal agents (UHRA-9 and UHRA-10) vs. Heparin was evaluated on Arterial thrombosis and bleeding. Administration of UHRA-9 or UHRA-10 significantly reduced arterial thrombosis in mice with significantly less bleeding compared with therapeutically equivalent doses of heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: